Omalizumab decreases exacerbations and allows a step down in daily inhaled corticosteroid dose in adults and children with moderate-to-severe asthma

Evidence-Based Medicine

Volumn 19, Issue 4, 2014, Pages 135-

  Thomson, Neil C ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIASTHMATIC AGENT; ANTIIDIOTYPIC ANTIBODY; IMMUNOGLOBULIN E; MONOCLONAL ANTIBODY;

ASTHMA; HUMAN; IMMUNOLOGY;

ANTI-ASTHMATIC AGENTS; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL, HUMANIZED; ASTHMA; HUMANS; IMMUNOGLOBULIN E;

EID: 84905921430     PISSN: 13565524     EISSN: 14736810     Source Type: Journal    
DOI: 10.1136/eb-2014-101759     Document Type: Review

References (5)

1. Thomson NC, Chaudhuri R. Omalizumab: clinical use for the management of asthma. Clin Med Insights Circ Respir Pulm Med 2012;6 :27-40.
2. British guideline on the management of asthma. A national clinical guideline. Thorax http://www.sign.ac.uk, 2012:1-144.
3. Walker S, Monteil M, Phelan K, et al. Anti-IgE for chronic asthma in adults and children. Cochrane Database of Syst Rev 2006;2:CD003559.
4. National Asthma Education and Prevention Program (National Heart, Lung, and Blood Institute). Expert panel report 3: guidelines for the diagnosis and management of asthma. NIH publication no 07-4051 Bethesda, Md: National Institutes of Health National Heart, Lung, and Blood Institute; 2007. http://www.nhlbi.nih.gov/ guidelines/asthma (accessed 17 Feb 2014).
5. Global Initiative for Asthma (GINA) Report, Global Strategy for Asthma Management and Prevention. www.ginasthma.com (accessed 17 Feb 2014).